Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

M. N. Zamotaeva; V. I. Inchina; V. V. Konorev; Yu. V. Kuznetsov; N. D. Kuz’michev

doi:10.1007/s10517-018-4166-y

Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

Авторы: Zamotaeva M.¹, Inchina V.¹, Konorev V.¹, Kuznetsov Y.², Kuz’michev N.¹
Учреждения:
1. N. P. Ogarev Mordovian National Research State University
2. N. M. Emanuel Institute of Biochemical Physics
Выпуск: Том 165, № 3 (2018)
Страницы: 344-346
Раздел: Article
URL: https://journals.rcsi.science/0007-4888/article/view/240286
DOI: https://doi.org/10.1007/s10517-018-4166-y
ID: 240286

Цитировать

Полный текст

Открытый доступ
Доступ закрыт

Доступ предоставлен
Доступ закрыт

Только для подписчиков

Аннотация
Об авторах
Список литературы
Статистика

Аннотация

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.